These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 31144295)
1. Loss of FBXO7 results in a Parkinson's-like dopaminergic degeneration via an RPL23-MDM2-TP53 pathway. Stott SR; Randle SJ; Al Rawi S; Rowicka PA; Harris R; Mason B; Xia J; Dalley JW; Barker RA; Laman H J Pathol; 2019 Oct; 249(2):241-254. PubMed ID: 31144295 [TBL] [Abstract][Full Text] [Related]
2. Impaired mitochondrial accumulation and Lewy pathology in neuron-specific FBXO7-deficient mice. Noda S; Sato S; Fukuda T; Ueno S; Tada N; Hattori N Mol Brain; 2022 Jun; 15(1):54. PubMed ID: 35701754 [TBL] [Abstract][Full Text] [Related]
3. Structure and Function of Fbxo7/PARK15 in Parkinson's Disease. Randle SJ; Laman H Curr Protein Pept Sci; 2017; 18(7):715-724. PubMed ID: 26965690 [TBL] [Abstract][Full Text] [Related]
4. Neural ablation of the PARK10 candidate Plpp3 leads to dopaminergic transmission deficits without neurodegeneration. Gómez-López S; Martínez-Silva AV; Montiel T; Osorio-Gómez D; Bermúdez-Rattoni F; Massieu L; Escalante-Alcalde D Sci Rep; 2016 Apr; 6():24028. PubMed ID: 27063549 [TBL] [Abstract][Full Text] [Related]
5. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485 [TBL] [Abstract][Full Text] [Related]
6. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons. Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638 [TBL] [Abstract][Full Text] [Related]
7. Dopaminergic neuronal loss and dopamine-dependent locomotor defects in Fbxo7-deficient zebrafish. Zhao T; Zondervan-van der Linde H; Severijnen LA; Oostra BA; Willemsen R; Bonifati V PLoS One; 2012; 7(11):e48911. PubMed ID: 23133663 [TBL] [Abstract][Full Text] [Related]
8. FBXO7 triggers caspase 8-mediated proteolysis of the transcription factor FOXO4 and exacerbates neuronal cytotoxicity. Lee SH; Jung S; Lee YJ; Hyun M; Chung KC J Biol Chem; 2021 Dec; 297(6):101426. PubMed ID: 34800438 [TBL] [Abstract][Full Text] [Related]
9. Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration. Kim H; Shin JY; Jo A; Kim JH; Park S; Choi JY; Kang HC; Dawson VL; Dawson TM; Shin JH; Lee Y Brain; 2021 Dec; 144(12):3674-3691. PubMed ID: 34581802 [TBL] [Abstract][Full Text] [Related]
10. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317 [TBL] [Abstract][Full Text] [Related]
11. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer. Zhang YF; Zhang BC; Zhang AR; Wu TT; Liu J; Yu LF; Wang WX; Gao JF; Fang DC; Rao ZG Oncol Rep; 2013 Oct; 30(4):1989-95. PubMed ID: 23933826 [TBL] [Abstract][Full Text] [Related]
12. Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). Zhao T; De Graaff E; Breedveld GJ; Loda A; Severijnen LA; Wouters CH; Verheijen FW; Dekker MC; Montagna P; Willemsen R; Oostra BA; Bonifati V PLoS One; 2011 Feb; 6(2):e16983. PubMed ID: 21347293 [TBL] [Abstract][Full Text] [Related]
13. Gsk3β and Tomm20 are substrates of the SCFFbxo7/PARK15 ubiquitin ligase associated with Parkinson's disease. Teixeira FR; Randle SJ; Patel SP; Mevissen TE; Zenkeviciute G; Koide T; Komander D; Laman H Biochem J; 2016 Oct; 473(20):3563-3580. PubMed ID: 27503909 [TBL] [Abstract][Full Text] [Related]
14. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress. Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429 [TBL] [Abstract][Full Text] [Related]
15. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity. Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798 [TBL] [Abstract][Full Text] [Related]
16. Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. Lin X; Parisiadou L; Sgobio C; Liu G; Yu J; Sun L; Shim H; Gu XL; Luo J; Long CX; Ding J; Mateo Y; Sullivan PH; Wu LG; Goldstein DS; Lovinger D; Cai H J Neurosci; 2012 Jul; 32(27):9248-64. PubMed ID: 22764233 [TBL] [Abstract][Full Text] [Related]
17. RPL23 Links Oncogenic RAS Signaling to p53-Mediated Tumor Suppression. Meng X; Tackmann NR; Liu S; Yang J; Dong J; Wu C; Cox AD; Zhang Y Cancer Res; 2016 Sep; 76(17):5030-9. PubMed ID: 27402081 [TBL] [Abstract][Full Text] [Related]